Drug prices in several disease areas outpace other healthcare expenditures and result in inadequate availability of essential medicines globally, according to a recently published review.
The cost of the cancer drug Gleevec tripled after the FDA approved a new indication, the $1000-per-pill hepatitis C virus (HCV) treatment Sovaldi accounted for 64% of US HCV-related spending in 2014, and the cost of the 60-year-old drug Daraprim went from $13.50 per pill to $750 per pill after Turing Pharmaceuticals acquired its distribution license. Reports like these led to hearings in the US Congress examining the pricing practices of pharmaceutical companies. In the United Kingdom, costly cancer immunotherapies faced rejection for National Health Service coverage reimbursement, and the German government is planning to curb pharmaceutical companies’ right to set launch prices. The sharply rising prices of prescription medications even became an issue in the 2016 US presidential election.
Drug prices in several disease areas outpace other healthcare expenditures and result in inadequate availability of essential medicines globally, according to a review by Toon van der Gronde, PharmD, and colleagues in a recent issue of PLOS One. They note that high prices for medicines, however innovative, are untenable and often beyond the ability of individuals, health insurance companies, or even governments in high-income countries to pay. Health systems therefore face a challenge in striking a balance between rewarding investments in innovation, achieving reasonable drug prices, and securing equitable access to medicines—a challenge that demands new policies to prevent a continued drug pricing spiral, van der Gronde and colleagues conclude.
The investigators searched PubMed for peer-reviewed English-language scientific articles on drugs and cost as well as reputable news outlets such as the Financial Times, The New York Times, the Wall Street Journal, and The Guardian for articles concerning the pricing of medicines between January 2014 and January 2017. Their review first examines the concepts of drug life-cycle dynamics, government interventions aimed at reducing drug prices, and the consequences of those interventions, and then suggests alternative policy measures to reduce drug prices and improve access to innovative and essential medications.
Van der Gronde and colleagues argue that fertile ground for high-priced drugs was created by several factors:
Van der Gronde and colleagues recommend the following steps to reduce drug prices:
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.